RGNX has been the topic of several other research reports. Chardan Capital reiterated a buy rating on shares of Regenxbio in a report on Monday, August 22nd. Zacks Investment Research upgraded Regenxbio from a sell rating to a hold rating in a report on Friday, August 26th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $26.75.
Shares of Regenxbio (NASDAQ:RGNX) traded down 1.40% during trading on Monday, reaching $17.57. The company’s stock had a trading volume of 202,800 shares. The stock’s 50 day moving average price is $13.90 and its 200 day moving average price is $11.22. The company’s market cap is $464.99 million. Regenxbio has a 52 week low of $7.07 and a 52 week high of $25.00.
Regenxbio (NASDAQ:RGNX) last issued its earnings results on Tuesday, August 9th. The company reported ($0.55) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.53) by $0.02. Regenxbio had a negative return on equity of 17.89% and a negative net margin of 451.73%. Equities research analysts predict that Regenxbio will post ($2.37) EPS for the current year.
Large investors have recently added to or reduced their stakes in the stock. BlackRock Institutional Trust Company N.A. boosted its stake in Regenxbio by 90.6% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 58,821 shares of the company’s stock valued at $635,000 after buying an additional 27,960 shares during the last quarter. State Street Corp boosted its stake in Regenxbio by 53.0% in the first quarter. State Street Corp now owns 88,025 shares of the company’s stock valued at $950,000 after buying an additional 30,500 shares during the last quarter. Geode Capital Management LLC boosted its stake in Regenxbio by 16.9% in the first quarter. Geode Capital Management LLC now owns 57,142 shares of the company’s stock valued at $617,000 after buying an additional 8,255 shares during the last quarter. Sabby Management LLC boosted its stake in Regenxbio by 157.0% in the first quarter. Sabby Management LLC now owns 300,329 shares of the company’s stock valued at $3,244,000 after buying an additional 183,469 shares during the last quarter. Finally, Vivo Capital LLC purchased a new stake in Regenxbio during the first quarter valued at approximately $10,697,000. Hedge funds and other institutional investors own 68.73% of the company’s stock.
REGENXBIO Inc is a biotechnology company. The Company is focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. Its AAV gene delivery platform (its NAV Technology Platform) consists of rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).
Receive News & Ratings for Regenxbio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.